Valeant walks away from ISTA bid; Grape seed extract could be promising for head and neck cancer;

@FierceBiotech: BREAKING: Roche wins landmark approval for targeted skin cancer drug vismodegib. News | Follow @FierceBiotech

@JohnCFierce: Cell Therapeutics pulls its pixantrone app, presumably so they can keep saying how certain they are of an approval. Release | Follow @JohnCFierce

@RyanMFierce: An example of a DNA sequencing success in medicine where children of $LIFE employee benefited. Article | Follow @RyanMFierce

@MarkHFierce: Grape seed extract is the latest potential cancer drug. More | Follow @MarkHFierce

> Valeant Pharmaceuticals ($VRX) is walking away from its bid to acquire ISTA for $353 million citing a lack of progress. Dealmakers note: Valeant CEO Michael Pearson loves to play hardball. Story

> An independent committee is recommending the continuation of the Phase III study for palifosfamide, according to Ziopharm. More

Pharma News

@FiercePharma: GSK is shopping for deals in Turkey, exec says; companies w/ CV drugs, manufacturing among possible targets--Bloomberg. More | Follow @FiercePharma

> Lipitor brand loses ground as generics take hold. Story

> FDA weighs crackdown on 'distracting images' in DTC ads. Article

> Ax hovers over 3,000 more AstraZeneca jobs, U.K. papers say. News

IT News

> Google Ventures, VCs backing tech focused on genomics. More

> U.K. genomics database plan faces hurdles. Story

> Covance's big IT budget gets thumbs down from analysts. Article

> Gamers tackle enzyme makeover, beat scientists' efforts. News

> Emerging player in DNA analysis joins forces with U. of Missouri. More

Medical Device News

> Abbott to cut 700 jobs as Promus sales decline. Story

> Roche's $5.7B Illumina bid risks standing alone. Article

> Covidien sees strength in medical device unit as profits rise. News

> KCI installs new CEO, chairman. More

And Finally... Investigators say that grape seed extract killed head and neck squamous cell carcinoma cells, while leaving healthy cells unharmed. Release

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.